Page 20 of 24: studies 381 to 400 of 466, newest first. Back to the depression overview
Nursing Open January 24, 2023 Hui Liu, L. Kong, Qian Sun et al.
This meta‐analysis aimed to determine the effect of mindfulness interventions on nurses' levels of depression and anxiety.
Pharmaceuticals January 24, 2023 Adam Włodarczyk, Alicja Dywel, Wiesław Jerzy Cubała 10 citations
There is evidence for ketamine use in treatment-resistant depression (TRD). Several safety concerns arise regarding adverse drug reactions in specific subpopulations. The aim of this study was to investigate the safety of intravenous ketamine treatment in relation to dissociative and psychotic measures in TRD inpatients with Major Depressive Disorder (MDD) and Bipolar depression (BP) with...
Cancer Nursing January 23, 2023 Bixia Zhang, Xiaohuan Jin, X. Kuang et al.
Background Emerging evidence supports that virtual reality (VR)–based meditation interventions may improve anxiety and depression among patients with cancer. However, empirical studies involving patients with acute leukemia during induction chemotherapy are limited. Objective This study aimed to examine the effects of VR-based meditation intervention on alleviating anxiety and depression and...
Pharmacoeconomics January 20, 2023 Carla Rognoni, Camilla Falivena, Francesco Costa et al.
Aim: Major depressive disorder is considered one of the most frequent diseases in the general population, and treatment-resistant depression (TRD) represents the subset with more significant clinical and social impact. Large, robust phase III studies have shown safety and efficacy of esketamine nasal spray plus SSRI/SNRI antidepressants (ADs) compared with SSRI/SNRI plus placebo nasal spray in...
Molecular Psychiatry January 20, 2023 Jie Guo, Di Qiu, Han-Wen Gu et al. 46 citations
Ketamine, a commonly used general anesthetic, can produce rapid and sustained antidepressant effect. However, the efficacy and safety of the perioperative application of ketamine on postoperative depression remains uncertain. We performed a meta-analysis to determine the effect of perioperative intravenous administration of ketamine on postoperative depression. Randomized controlled trials...
The World Journal of Biological Psychiatry January 18, 2023 Shakila Meshkat, Sipan Haikazian, Joshua D. Di Vincenzo et al. 61 citations
Abstract Objectives: Ketamine is a glutamate N-methyl-D-aspartate receptor antagonist that can be used to treat major depressive disorder by single or repeated infusions. However, the accessibility and scalability of oral ketamine make it preferred over intravenous ketamine. In this systematic review, we aim to evaluate the efficacy, tolerability, and safety of oral ketamine, esketamine and...
International Journal of Research in Medical Sciences January 17, 2023 Ubaid Rasool, Neelofer Jan, Marya Zahoor et al. 3 citations
Background: Treatment resistant depression can be a life-threatening condition as it leads to an increase of suicide attempts by two to three folds. It has been estimated that nearly 1 million people die due to suicide every year, and more than two-third of these cases occur when the person is undergoing a major depressive episode. Ketamine is an NMDA receptor antagonist, an anesthetic agent...
medRxiv January 17, 2023 Ryan Yermus, Michael Verbora, Sidney H. Kennedy et al. 2 citations preprint
Abstract IMPORTANCE Ketamine-Assisted Psychotherapy (KAP) is an emerging treatment option to alleviate treatment resistant affective disorders, but its long term effectiveness remains unclear. OBJECTIVE To examine the treatment effects of KAP on anxiety, depression, and post traumatic stress disorder (PTSD) at 1, 3, and 6 months post treatment. DESIGN, SETTING, AND PARTICIPANTS This...
AIDASCO Reviews January 17, 2023 Dragana Marković, Eleonora Čapelja 2 citations
Major depressive disorder (MDD), also known as clinical depression, is a serious mental disorder and ranks first among psychiatric disorders that dominate the global disease burden. Recently, it was found that psilocybin, active compound derived from psychotropic mushrooms, can relieve depression symptoms rapidly and sustained benefits for several months. Beside MDD, psilocybin can alleviate...
Journal of Psychedelic Studies January 16, 2023 Madeline Brendle, Anya Ragnhildstveit, Matthew Slayton et al. 7 citations
Ketamine and esketamine have garnered interest in both psychiatric research and clinical practice for treatment-resistant depression (TRD). In this review, we examined registered trials investigating the therapeutic use of ketamine or esketamine for TRD, with the aim of characterizing emerging trends and knowledge gaps.The ClinicalTrials.gov electronic registry and results database was queried...
International Journal of Environmental Research and Public Health January 14, 2023 Hui-Wen Tseng, Fan-Hao Chou, Ching-Hsiu Chen et al.
This study synthesizes the effect of mindfulness-based cognitive therapy (MBCT) on depression and suicidal ideation among patients with major depressive disorder (MDD). During treatment, patients with MDD may experience repeated episodes, negative counseling, and suicidal ideation, which can lead to further depression and ultimately affect quality of life. Recent studies have shown that MBCT...
Bipolar Disorders January 13, 2023 Giovanni Martinotti, Bernardo Dell’osso, Giorgio Di Lorenzo et al. 72 citations
BACKGROUND: Bipolar depression accounts for most of the disease duration in type I and type II bipolar disorder (BD), with few treatment options, often poorly tolerated. Many individuals do not respond to first-line therapeutic options, resulting in treatment-resistant bipolar depression (B-TRD). Esketamine, the S-enantiomer of ketamine, has recently been approved for treatment-resistant...
Brain Sciences January 13, 2023 Maria Gałuszko‐węgielnik, Zuzanna Chmielewska, Katarzyna Jakuszkowiak‐wojten et al. 20 citations
Psychotic treatment-resistant depression is a complex and challenging manifestation of mood disorders in the clinical setting. Psychotic depression is a subtype of major depressive disorder characterized by mood-consistent hallucinations and/or delusions. Psychotic depression is often underdiagnosed and undertreated. Ketamine appears to have rapid and potent antidepressant effects in clinical...
Med January 13, 2023 Natalie Gukasyan 12 citations
Results from a recent Phase II trial of psilocybin-assisted therapy for treatment-resistant depression1 suggest modest efficacy but raise concerns about potential for serious adverse effects. The study highlights the need for rigorous assessment of blinding integrity, expectancy, and further study of factors that may contribute to risk in vulnerable populations.
BMC Psychology January 12, 2023 Jennifer E S Beauchamp, Anjail Sharrief, Alejandro Chaoul et al.
Depressive symptoms are a significant psychological complication of stroke, impacting both survivors and informal caregivers of survivors. Randomized controlled trials are needed to determine optimal non-pharmacological strategies to prevent or ameliorate depressive symptoms in stroke survivors and their informal caregivers. A prospective, randomized, parallel-group, single-center, feasibility...
Annals of Pharmacotherapy January 12, 2023 C Michael White, Nissen Weisman, Joseph Dalo 18 citations
Objective: To assess the role of psychedelics in the treatment of anxiety or depression among patients with cancer. Data Sources: PubMed search from inception to March 11, 2022, using the terms anxiety, depression, psychedelics, psilocybin, lysergic acid, methylenedioxymethamphetamine, or ayahuasca. Study Selection and Data Extraction: Studies assessing patients with cancer receiving...
Frontiers in Psychiatry January 10, 2023 Jennifer Warner-Schmidt, Christopher Pittenger, Martin Stogniew et al. 11 citations
Introduction Selective serotonin reuptake inhibitor (SSRI) antidepressants represent first-line pharmacological treatment for a variety of neuropsychiatric illnesses, including major depressive disorder (MDD), anxiety, and post-traumatic stress disorder (PTSD), which show high rates of comorbidity. SSRIs have a delayed onset of action. Most patients do not show significant effects until 4–8...
Frontiers in Psychiatry January 9, 2023 Abdullah Al Ozairi, Dalal Alsaeed, Ebaa Al-Ozairi et al.
Background: The outbreak of coronavirus disease 2019 (COVID-19) created unprecedented stress on physicians. Mindfulness is a type of meditation that focuses on being fully present, aware of senses, and emotions in the present moment without analyzing or judging them, and it may help reduce psychological distress in physicians. This study aimed to examine the effectiveness of virtual...
Frontiers in Public Health January 9, 2023 Hongyang Liu, Kexin Cai, Jinyang Wang et al.
BackgroundMindfulness-based interventions (MBIs) are psychological interventions widely used in menopausal women. Currently, there is no evidence summary on the effectiveness of MBIs on anxiety, depression, stress, and mindfulness in menopausal women. This meta-analysis examines the effectiveness of MBIs in improving anxiety, depression, stress, and mindfulness scores in menopausal...
Cancers January 7, 2023 Joshua D. Rosenblat, Froukje E. deVries, Zoe Doyle et al. 49 citations
Antidepressants require several weeks for the onset of action, a lag time that may exceed life expectancy in palliative care. Ketamine has demonstrated rapid antidepressant effects, but has been minimally studied in cancer and palliative care populations. Herein, the objective was to determine the feasibility, safety, tolerability and preliminary efficacy of intranasal racemic ketamine for...